[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 443
61. Gómez-Román VR, Patterson LJ, Venzon D, Liewehr D, Aldrich K, Florese R, Robert-Guroff M: Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol; 2005 Feb 15;174(4):2185-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Effector cells armed with Abs can eliminate virus-infected target cells by Ab-dependent cellular cytotoxicity (ADCC), an immune mechanism that has been largely overlooked in HIV vaccine development.
  • Here, we show that a prime/boost AIDS vaccine approach elicits potent ADCC activity correlating with protection against SIV in rhesus macaques (Macacca mulatta).
  • Priming with replicating adenovirus type 5 host range mutant-SIV recombinants, followed by boosting with SIV gp120, elicited Abs with ADCC activity against SIV(mac251)-infected cells.
  • In vitro ADCC activity correlated with in vivo reduced acute viremia after a mucosal challenge with pathogenic SIV.
  • Our findings expose ADCC activity as an immune correlate that may be relevant in the rational design of an efficacious vaccine against HIV.

  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - HIV InSite .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15699150.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Gene Products, env; 0 / Immunoglobulin G; 0 / SAIDS Vaccines; 0 / Vaccines, Synthetic
  •  go-up   go-down


62. Zhang LY, Yam GH, Tam PO, Lai RY, Lam DS, Pang CP, Fan DS: An alphaA-crystallin gene mutation, Arg12Cys, causing inherited cataract-microcornea exhibits an altered heat-shock response. Mol Vis; 2009;15:1127-38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A heterozygous missense substitution, c.34C>T, in CRYAA, which is responsible for the R12C amino acid change, segregated with autosomal dominant cataract (ADCC) in this family.
  • The altered heat-shock response of mutant cells suggested a change of chaperoning capacity and networking, which could be associated with the pathogenesis of hereditary cataract-microcornea syndrome.

  • MedlinePlus Health Information. consumer health - Cataract.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mol Genet. 1998 Mar;7(3):471-4 [9467006.001]
  • [Cites] Biochemistry. 1997 Aug 19;36(33):9951-7 [9296605.001]
  • [Cites] Protein Sci. 2005 Mar;14(3):569-81 [15722442.001]
  • [Cites] Cell Stress Chaperones. 2005 Spring;10(1):66-78 [15832949.001]
  • [Cites] Mol Vis. 2005;11:321-7 [15889016.001]
  • [Cites] Protein Sci. 2005 Aug;14(8):2030-43 [16046626.001]
  • [Cites] Mol Vis. 2005;11:587-93 [16110300.001]
  • [Cites] Am J Med Genet A. 2006 Mar 15;140(6):558-66 [16470690.001]
  • [Cites] Mol Vis. 2006;12:190-5 [16604058.001]
  • [Cites] Mol Vis. 2006;12:518-22 [16735993.001]
  • [Cites] Mol Vis. 2006;12:768-73 [16862070.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2006 Aug;244(8):912-9 [16453125.001]
  • [Cites] Arch Ophthalmol. 2007 Feb;125(2):165-73 [17296892.001]
  • [Cites] Arch Ophthalmol. 2007 Feb;125(2):213-6 [17296897.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2007 Apr;48(4):1683-90 [17389500.001]
  • [Cites] Biopolymers. 2007 Jun 15;86(3):177-92 [17345631.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2007 Sep;48(9):3937-44 [17724170.001]
  • [Cites] Mol Vis. 2007;13:2019-22 [17982426.001]
  • [Cites] Am J Ophthalmol. 2007 Dec;144(6):949-952 [17937925.001]
  • [Cites] Orphanet J Rare Dis. 2007;2:47 [18039390.001]
  • [Cites] Semin Cell Dev Biol. 2008 Apr;19(2):134-49 [18035564.001]
  • [Cites] Am J Hum Genet. 2008 Mar;82(3):772-9 [18304496.001]
  • [Cites] Am J Med Genet A. 2008 Apr 1;146A(7):833-42 [18302245.001]
  • [Cites] Acta Ophthalmol Scand. 1999 Oct;77(5):578-80 [10551305.001]
  • [Cites] J Biol Chem. 2000 Feb 11;275(6):3767-71 [10660525.001]
  • [Cites] Biochemistry. 2000 Feb 15;39(6):1420-6 [10684623.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2000 Oct;41(11):3511-5 [11006246.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2001 Jun;42(7):1444-8 [11381045.001]
  • [Cites] J Cell Biochem. 2001;82(3):409-14 [11500917.001]
  • [Cites] Eur J Biochem. 2001 Dec;268(24):6335-45 [11737188.001]
  • [Cites] Hum Mol Genet. 2002 Jan 1;11(1):33-42 [11772997.001]
  • [Cites] J Cell Biochem. 2002;84(2):278-84 [11787056.001]
  • [Cites] Mech Dev. 2002 Mar;112(1-2):213-5 [11850198.001]
  • [Cites] Br J Ophthalmol. 2002 Jul;86(7):782-6 [12084750.001]
  • [Cites] Environ Health Perspect. 2002 Oct;110(10):1041-6 [12361930.001]
  • [Cites] Br J Ophthalmol. 2003 Feb;87(2):197-202 [12543751.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2003 Mar;44(3):1155-9 [12601044.001]
  • [Cites] Ophthalmic Epidemiol. 2003 Apr;10(2):67-74 [12660855.001]
  • [Cites] Eur J Hum Genet. 2003 Oct;11(10):784-93 [14512969.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2004 May;45(5):1316-20 [15111583.001]
  • [Cites] Surv Ophthalmol. 2004 May-Jun;49(3):300-15 [15110667.001]
  • [Cites] Science. 1989 Oct 20;246(4928):382-5 [2799391.001]
  • [Cites] Exp Eye Res. 1994 Apr;58(4):381-7 [7925675.001]
  • [Cites] Nature. 1996 Jun 13;381(6583):571-9 [8637592.001]
  • [Cites] EMBO J. 1996 Jun 17;15(12):2969-79 [8670798.001]
  • [Cites] J Biol Chem. 1997 Aug 15;272(33):20427-34 [9252351.001]
  • [Cites] Mol Vis. 1999 Sep 10;5:21 [10493778.001]
  • (PMID = 19503744.001).
  • [ISSN] 1090-0535
  • [Journal-full-title] Molecular vision
  • [ISO-abbreviation] Mol. Vis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CRYAA protein, human; 0 / Crystallins; 0 / Heat-Shock Proteins
  • [Other-IDs] NLM/ PMC2690964
  •  go-up   go-down


63. Wong AW, Baginski TK, Reilly DE: Enhancement of DNA uptake in FUT8-deleted CHO cells for transient production of afucosylated antibodies. Biotechnol Bioeng; 2010 Aug 1;106(5):751-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Removal of the core alpha1,6 fucose from the glycans in the Fc region of IgG1 antibodies has been demonstrated to improve antibody-dependent cellular cytotoxicity (ADCC) activity.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley Periodicals, Inc.
  • (PMID = 20564613.001).
  • [ISSN] 1097-0290
  • [Journal-full-title] Biotechnology and bioengineering
  • [ISO-abbreviation] Biotechnol. Bioeng.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Recombinant Proteins; 9007-49-2 / DNA; EC 2.4.1.- / Fucosyltransferases
  •  go-up   go-down


6
Advertisement
4. Tang W, Chen G, Gu Q, Pan J, Wu W: Expression, purification and identification of recombinant mouse interleukin 21 protein in E. coli. Cell Mol Immunol; 2006 Aug;3(4):311-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • IL-21 is capable of co-stimulating mature T cells, B cells, NK cells, and of stimulating CD16 expression on the surface of NK cells to induce ADCC in innate immune response.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17083198.001).
  • [ISSN] 1672-7681
  • [Journal-full-title] Cellular & molecular immunology
  • [ISO-abbreviation] Cell. Mol. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Interleukins; 0 / Recombinant Proteins; 0 / interleukin-21
  •  go-up   go-down


65. Friedberg JW, Kelly JL, Neuberg D, Peterson DR, Kutok JL, Salloum R, Brenn T, Fisher DC, Ronan E, Dalton V, Rich L, Marquis D, Sims P, Rothberg PG, Liesveld J, Fisher RI, Coffman R, Mosmann T, Freedman AS: Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol; 2009 Aug;146(3):282-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Toll-like receptor-9 (TLR-9) agonists have pleotropic effects on both the innate and adaptive immune systems, including increased antigen expression, enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) and T helper cell type 1 shift in the immune response.
  • Biologically relevant increases in ADCC and circulating CD-3 positive T cells were observed in 35% and 39% of patients, respectively.

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunother. 2006 Sep-Oct;29(5):558-68 [16971811.001]
  • [Cites] Curr Treat Options Oncol. 2006 Jul;7(4):276-84 [16916488.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5350-7 [17135637.001]
  • [Cites] Int Immunopharmacol. 2006 Dec 20;6(13-14):2057-68 [17161362.001]
  • [Cites] Clin Immunol. 2007 Feb;122(2):139-45 [17008130.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):388-97 [17255259.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2008-13 [17068155.001]
  • [Cites] J Immunol. 2007 Aug 15;179(4):2493-500 [17675511.001]
  • [Cites] Clin Cancer Res. 2007 Oct 15;13(20):6168-74 [17947483.001]
  • [Cites] Exp Hematol. 2008 Jan;36(1):69-77 [17959301.001]
  • [Cites] Oncogene. 2008 Jan 7;27(2):161-7 [18176597.001]
  • [Cites] Semin Hematol. 2008 Apr;45(2):71-4 [18381100.001]
  • [Cites] Semin Hematol. 2008 Apr;45(2):85-9 [18381102.001]
  • [Cites] Leuk Lymphoma. 2008 May;49(5):902-9 [18464109.001]
  • [Cites] J Clin Oncol. 2008 Jun 1;26(16):2725-31 [18427151.001]
  • [Cites] J Clin Oncol. 2008 Aug 20;26(24):3979-86 [18711188.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2644-52 [10914705.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Clin Cancer Res. 2008 Sep 1;14(17):5626-34 [18765557.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3135-43 [10963642.001]
  • [Cites] Blood. 2002 Jan 1;99(1):67-74 [11756154.001]
  • [Cites] Br J Haematol. 2002 Jun;117(4):828-34 [12060117.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3940-7 [12975461.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2253-64 [15073100.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4416-23 [14976046.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5297-8 [15328164.001]
  • [Cites] Annu Rev Immunol. 1989;7:145-73 [2523712.001]
  • [Cites] J Cell Biochem. 1991 Apr;45(4):381-90 [1675219.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] J Clin Invest. 1997 Sep 1;100(5):1059-70 [9276722.001]
  • [Cites] N Engl J Med. 2004 Nov 18;351(21):2159-69 [15548776.001]
  • [Cites] Blood. 2005 Jan 15;105(2):489-95 [15358617.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1088-95 [15657401.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1490-9 [15746051.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5019-26 [15983392.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2169-74 [15933054.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1675-82 [16030029.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8447-52 [16230674.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:329-34 [16304399.001]
  • [Cites] Cell. 2006 Feb 24;124(4):783-801 [16497588.001]
  • [Cites] Blood. 2006 Nov 1;108(9):2957-64 [16825494.001]
  • (PMID = 19519691.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / RR 024160; United States / NCI NIH HHS / CA / K23 CA102216; United States / PHS HHS / / A1054953; United States / NHLBI NIH HHS / HL / T32 HL007152; United States / NCI NIH HHS / CA / R21 CA103244; United States / NHLBI NIH HHS / HL / HL-007152; United States / NCI NIH HHS / CA / CA-102216; United States / NCI NIH HHS / CA / CA-103244; United States / NCRR NIH HHS / RR / UL1 RR024160; United States / NCI NIH HHS / CA / K23 CA102216-05; United States / NIAID NIH HHS / AI / R24 AI054953
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 1018 oligonucleotide; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Chemokine CCL2; 0 / Chemokine CXCL10; 0 / IFIT2 protein, human; 0 / Oligodeoxyribonucleotides; 0 / Proteins; 0 / Toll-Like Receptor 9; 4F4X42SYQ6 / Rituximab; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ NIHMS139957; NLM/ PMC2747261
  •  go-up   go-down


66. Cassard L, Cohen-Solal JF, Fournier EM, Camilleri-Broët S, Spatz A, Chouaïb S, Badoual C, Varin A, Fisson S, Duvillard P, Boix C, Loncar SM, Sastre-Garau X, Houghton AN, Avril MF, Gresser I, Fridman WH, Sautès-Fridman C: Selective expression of inhibitory Fcgamma receptor by metastatic melanoma impairs tumor susceptibility to IgG-dependent cellular response. Int J Cancer; 2008 Dec 15;123(12):2832-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We show that FcgammaRIIB expression prevents the lysis of human metastatic melanoma cells by NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) in vitro, independently of the intracytoplasmic region of FcgammaRIIB.
  • Using experimental mouse models, we demonstrate that expression of FcgammaRIIB protects B16F0 melanoma tumors from the ADCC induced by monoclonal and polyclonal anti-tumor IgG in vivo.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18798552.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Fc gamma receptor IIB; 0 / Immunoglobulin G; 0 / Receptors, IgG
  •  go-up   go-down


67. Sumonwiriya M, Horhthongkham N, Pattanapanyasat K, Ampol S, Sutthent R, Kantakamalakul W: Stable expression of EBV-gp350 on the surface of NC37 cells confers natural killer (NK)-cell susceptibility or resistance, depending on the assay used to assess NK-mediated function. J Virol Methods; 2009 Oct;161(1):154-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EBV-gp350 has been identified as a ligand for antibody dependent cell-mediated cytotoxicity (ADCC).
  • The stable expression of gp350 on the NC37 cell surface membrane could make this cell line a suitable target for measuring ADCC antibody.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19539652.001).
  • [ISSN] 1879-0984
  • [Journal-full-title] Journal of virological methods
  • [ISO-abbreviation] J. Virol. Methods
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Chromium Radioisotopes; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Viral Matrix Proteins; 0 / enhanced green fluorescent protein; 147336-22-9 / Green Fluorescent Proteins
  •  go-up   go-down


68. Xiong Y, Cao C, Makarova A, Hyman B, Zhang L: Mac-1 promotes FcgammaRIIA-dependent cell spreading and migration on immune complexes. Biochemistry; 2006 Jul 25;45(29):8721-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The integrin Mac-1 plays a critical role in Fc receptor (FcR)-mediated antibody-dependent cellular cytotoxicity (ADCC).
  • Altogether, these results demonstrate that FcgammaRIIA recognizes Mac-1 via the alpha(M)I-domain but not the lectin domain, a distinct feature from other FcRs, and that Mac-1 binding confers FcgammaRIIA with the ability to prolong cell adhesion as well as to spread and migrate on the ICs, leading to effective cell killing by ADCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Immunol. 1993 May;148(2):385-96 [8098672.001]
  • [Cites] J Immunol. 2003 Nov 15;171(10):5124-9 [14607911.001]
  • [Cites] J Cell Biol. 1994 Jun;125(6):1407-16 [7515890.001]
  • [Cites] J Biol Chem. 1994 Oct 21;269(42):26419-23 [7929363.001]
  • [Cites] Leuk Res. 1995 Jan;19(1):57-64 [7837818.001]
  • [Cites] J Mol Biol. 1995 Apr 7;247(4):597-603 [7723017.001]
  • [Cites] J Immunol. 1995 Oct 1;155(7):3281-5 [7561018.001]
  • [Cites] J Biol Chem. 1996 Jul 26;271(30):18211-6 [8663418.001]
  • [Cites] J Immunol. 1996 Aug 1;157(3):1184-92 [8757624.001]
  • [Cites] J Immunol. 1996 Dec 15;157(12):5660-5 [8955219.001]
  • [Cites] Transplantation. 1997 Jan 15;63(1):106-12 [9000670.001]
  • [Cites] Annu Rev Immunol. 1997;15:203-34 [9143687.001]
  • [Cites] J Biol Chem. 1997 Jul 11;272(28):17558-64 [9211902.001]
  • [Cites] J Exp Med. 1997 Dec 1;186(11):1853-63 [9382884.001]
  • [Cites] J Biol Chem. 1998 Apr 24;273(17):10556-66 [9553116.001]
  • [Cites] Nat Struct Biol. 1999 May;6(5):437-42 [10331870.001]
  • [Cites] J Cell Biol. 2005 Jan 31;168(3):501-11 [15684035.001]
  • [Cites] Immunity. 2001 Jun;14(6):693-704 [11420040.001]
  • [Cites] Science. 2001 Oct 12;294(5541):339-45 [11546839.001]
  • [Cites] Immunol Res. 2002;25(1):75-95 [11868935.001]
  • [Cites] Curr Opin Immunol. 2002 Dec;14(6):798-802 [12413532.001]
  • [Cites] Blood. 2003 Jan 1;101(1):253-8 [12485936.001]
  • [Cites] Nat Rev Drug Discov. 2003 Sep;2(9):703-16 [12951577.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3940-7 [12975461.001]
  • [Cites] Blood. 2001 Apr 15;97(8):2478-86 [11290613.001]
  • [Cites] J Immunol. 2001 May 1;166(9):5629-37 [11313403.001]
  • [Cites] Immunol Lett. 2003 Dec 15;90(2-3):137-43 [14687715.001]
  • [Cites] J Cell Sci. 2004 Oct 15;117(Pt 22):5437-45 [15466887.001]
  • [Cites] Blood. 1992 Mar 15;79(6):1484-90 [1347707.001]
  • [Cites] J Immunol. 1992 Jun 1;148(11):3550-3 [1534099.001]
  • [Cites] J Cell Biol. 1993 Mar;120(6):1509-17 [8383692.001]
  • [Cites] J Immunol. 1993 Apr 1;150(7):3030-41 [7681086.001]
  • [Cites] J Immunol. 1993 May 15;150(10):4571-80 [8097757.001]
  • [Cites] J Biol Chem. 2003 Nov 14;278(46):45720-9 [12941957.001]
  • [Cites] J Leukoc Biol. 1994 Jun;55(6):735-42 [7910840.001]
  • (PMID = 16846215.001).
  • [ISSN] 0006-2960
  • [Journal-full-title] Biochemistry
  • [ISO-abbreviation] Biochemistry
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL061589; United States / NHLBI NIH HHS / HL / HL061589-05; United States / NHLBI NIH HHS / HL / P01 HL054710; United States / NHLBI NIH HHS / HL / R01 HL061589-05; United States / NHLBI NIH HHS / HL / R01 HL61589-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigen-Antibody Complex; 0 / Antigens, CD; 0 / Fc gamma receptor IIA; 0 / Macrophage-1 Antigen; 0 / Receptors, IgG
  • [Other-IDs] NLM/ NIHMS64482; NLM/ PMC2597675
  •  go-up   go-down


69. Gupta N, Arthos J, Khazanie P, Steenbeke TD, Censoplano NM, Chung EA, Cruz CC, Chaikin MA, Daucher M, Kottilil S, Mavilio D, Schuck P, Sun PD, Rabin RL, Radaev S, Van Ryk D, Cicala C, Fauci AS: Targeted lysis of HIV-infected cells by natural killer cells armed and triggered by a recombinant immunoglobulin fusion protein: implications for immunotherapy. Virology; 2005 Feb 20;332(2):491-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The adaptive response typically requires that virus-specific antibodies decorate infected cells which then direct NK cell lysis through a CD16 mediated process termed antibody-dependent cellular cytotoxicity (ADCC).

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15680414.001).
  • [ISSN] 0042-6822
  • [Journal-full-title] Virology
  • [ISO-abbreviation] Virology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Immunoglobulin G; 0 / Receptors, IgG
  •  go-up   go-down


70. Yan L, Ehrlich PJ, Gibson R, Pickett C, Beckman RA: How can we improve antibody-based cancer therapy? MAbs; 2009 Jan-Feb;1(1):67-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (2) improvements in biodistribution to maximize delivery of mAbs to susceptible tumor cells; and (3) optimization of antibody immune effector mechanisms such as antibody-dependent cellular cytotoxicity (ADCC).

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2006 Aug 18;281(33):23514-24 [16793771.001]
  • [Cites] Eur J Nucl Med. 1993 Apr;20(4):345-7 [8491228.001]
  • [Cites] Cancer. 2007 Jan 15;109(2):170-9 [17154393.001]
  • [Cites] Biotechniques. 2005 Oct;39(4):565-8 [16235569.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4005-10 [16537476.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2178-86 [17332348.001]
  • [Cites] Curr Opin Drug Discov Devel. 2007 Mar;10(2):153-9 [17436550.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3712-8 [17704420.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8882-90 [17875730.001]
  • [Cites] Drug Discov Today. 2007 Nov;12(21-22):898-910 [17993407.001]
  • [Cites] J Nucl Med. 2008 Mar;49(3):453-61 [18287274.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1626-34 [18316791.001]
  • [Cites] J Clin Oncol. 2008 Apr 10;26(11):1789-96 [18347005.001]
  • [Cites] Cancer J. 2008 May-Jun;14(3):178-83 [18536557.001]
  • [Cites] J Clin Oncol. 2008 Jul 10;26(20):3351-7 [18612151.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):366-77 [18596266.001]
  • [Cites] Curr Opin Immunol. 2008 Aug;20(4):471-8 [18606225.001]
  • [Cites] Curr Opin Immunol. 2008 Aug;20(4):460-70 [18656541.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):3992-5 [16618717.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2639-48 [10561337.001]
  • [Cites] J Control Release. 2000 Mar 1;65(1-2):271-84 [10699287.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • [Cites] Blood. 2002 Feb 1;99(3):754-8 [11806974.001]
  • [Cites] J Biol Chem. 2002 Jul 26;277(30):26733-40 [11986321.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1485-90 [12459375.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1288-96 [12649189.001]
  • [Cites] Hybrid Hybridomics. 2003 Feb;22(1):1-9 [12713684.001]
  • [Cites] Pharm Res. 2003 Sep;20(9):1337-50 [14567626.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3940-7 [12975461.001]
  • [Cites] Cancer Res. 1984 Jan;44(1):238-44 [6197161.001]
  • [Cites] J Nucl Med. 1990 Jul;31(7):1191-8 [2362198.001]
  • [Cites] Cancer Immunol Immunother. 1991;33(6):351-8 [1652355.001]
  • [Cites] Expert Opin Biol Ther. 2006 Nov;6(11):1161-73 [17049014.001]
  • (PMID = 20046576.001).
  • [ISSN] 1942-0870
  • [Journal-full-title] mAbs
  • [ISO-abbreviation] MAbs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2715179
  • [Keywords] NOTNLM ; biodistribution / bioengineering / cancer / monoclonal antibodies / pharmacogenomics / solid tumors
  •  go-up   go-down


71. Concetti F, Napolioni V: Insights into the role of Fc gamma receptors (FcgammaRs) genetic variations in monoclonal antibody-based anti-cancer therapy. Recent Pat Anticancer Drug Discov; 2010 Nov;5(3):197-204
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mechanisms behind their efficacy are multi-faceted; they can kill tumor cells through antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis as well as target ligands or growth factor receptors favoring tumor growth.
  • The interaction of the Fc domains of antibodies with the Fcgamma (gamma) receptors is an essential checkpoint in ADCC.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20594185.001).
  • [ISSN] 2212-3970
  • [Journal-full-title] Recent patents on anti-cancer drug discovery
  • [ISO-abbreviation] Recent Pat Anticancer Drug Discov
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Receptors, IgG
  •  go-up   go-down


72. Zhang M, Daniel S, Huang Y, Chancey C, Huang Q, Lei YF, Grinev A, Mostowski H, Rios M, Dayton A: Anti-West Nile virus activity of in vitro expanded human primary natural killer cells. BMC Immunol; 2010;11:3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expanded NK (D2NK) cell has strong natural killing activity against both K562 and Vero cells, and killed the WNV infected Vero cells through antibody-dependent cellular cytotoxicity (ADCC).

  • Genetic Alliance. consumer health - West nile virus.
  • MedlinePlus Health Information. consumer health - West Nile Virus.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2001 Jun;75(12):5663-71 [11356974.001]
  • [Cites] Emerg Infect Dis. 2008 Mar;14(3):436-44 [18325259.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Mar;31(3):403-7 [14685783.001]
  • [Cites] Stem Cells Dev. 2004 Jun;13(3):307-14 [15186726.001]
  • [Cites] Acta Virol. 1986 Jul;30(4):303-8 [2876611.001]
  • [Cites] Ann N Y Acad Sci. 1988;540:483-5 [2849899.001]
  • [Cites] J Neuroimmunol. 1989 Feb;21(2-3):157-68 [2463998.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Feb;86(3):911-5 [2492666.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3051-7 [15632206.001]
  • [Cites] Blood. 2005 Jul 1;106(1):376-83 [15755898.001]
  • [Cites] Sci STKE. 2005 Jul 12;2005(292):cm6 [16014603.001]
  • [Cites] Cytotherapy. 2005;7(1):16-22 [16040380.001]
  • [Cites] J Virol. 2006 Jan;80(1):119-29 [16352536.001]
  • [Cites] Transfusion. 2006 Apr;46(4):659-67 [16584445.001]
  • [Cites] Semin Cancer Biol. 2006 Oct;16(5):348-58 [16893656.001]
  • [Cites] Semin Cancer Biol. 2006 Oct;16(5):367-82 [16934486.001]
  • [Cites] Viral Immunol. 2003;16(3):259-78 [14583143.001]
  • (PMID = 20089143.001).
  • [ISSN] 1471-2172
  • [Journal-full-title] BMC immunology
  • [ISO-abbreviation] BMC Immunol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Blocking; 0 / Receptors, Natural Killer Cell; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ PMC2822749
  •  go-up   go-down


73. Zhu HL, Li Y, Chang XH, Cui H, Feng J, Wei LH: [Study of immunization protocol of ovarian carcinoma associated 6B11 anti-idiotypical minibody]. Zhonghua Fu Chan Ke Za Zhi; 2006 Jan;41(1):52-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study of immunization protocol of ovarian carcinoma associated 6B11 anti-idiotypical minibody].
  • Anti-anti-idiotypic antibody (Ab3) level was tested and antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) effect of mouse spleen cells to human ovarian carcinoma SKOV3 cells were measured using (51)Cr-release assay.
  • At four different effector cell/target cell (E/T) ratios, the ADCC was highest in group A and lowest in group C; when the E/T ratio was 1:125, (51)Cr releasing rate was 23% in group A, 17% in group B, and 12% in group C, the difference between groups A, B, C had statistical significance (P < 0.05).
  • CONCLUSION: 6B11 anti-idiotypic minibody of ovarian carcinoma can be used as tumor vaccine, the suitable immunization protocol in animals may be: prime at d(1), d(14) and d(28) at a dose of 100 microg; prime interval is six weeks.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16635330.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Anti-Idiotypic; 0 / Antibodies, Monoclonal; 0 / Cancer Vaccines
  •  go-up   go-down


74. Imai M, Landen C, Ohta R, Cheung NK, Tomlinson S: Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. Cancer Res; 2005 Nov 15;65(22):10562-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These data indicate a crucial role for antibody-dependent cell-mediated cytoxicity (ADCC).
  • However, at lower doses of IgG, therapeutic effect was partially abrogated in C3-deficient mice, indicating complement-mediated enhancement of ADCC at limiting IgG concentration.
  • Thus, IgG and IgM can operate via different primary mechanisms of action, and CDCC and complement-dependent enhancement of ADCC mechanisms are operative in vivo.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16288049.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCCIH NIH HHS / AT / AT002779; United States / NCI NIH HHS / CA / CA104579
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD2; 0 / Antigens, CD59; 0 / Complement C3; 0 / Immunoglobulin M; 0 / Receptors, IgG; 9007-36-7 / Complement System Proteins
  •  go-up   go-down


75. Saghravanian N, Mohtasham N, Jafarzadeh H: Comparison of immunohistochemical markers between adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma. J Oral Sci; 2009 Dec;51(4):509-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of immunohistochemical markers between adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma.
  • Adenoid cystic carcinoma (AdCC) and polymorphous low-grade adenocarcinoma (PLGA) have several common histological and clinicopathological features that may create diagnostic difficulties.
  • In this study, 10 AdCCs, 8 PLGAs, and 5 normal minor salivary glands as a control group were selected.
  • Data analysis showed high expression of CEA, MSA and Ki-67 in AdCCs compared with PLGAs, although CEA expression was limited to luminal cells.
  • The immunoreactivities of EMA and P53 were not helpful for distinguishing between the two tumors, although the EMA expression pattern in AdCCs was limited to luminal cells, whereas it was present in both luminal and non-luminal cells in PLGAs.
  • Thus, immunohistochemistry can be helpful for differential diagnosis of AdCC and PLGA, particularly that for CEA, vimentin, and Ki-67.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor. Carcinoma, Adenoid Cystic / chemistry. Salivary Gland Neoplasms / chemistry


76. Jazirehi AR, Bonavida B: Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene; 2005 Mar 24;24(13):2121-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The exact in vivo mechanisms of action of rituximab are not fully understood, although antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis have been suggested.


77. de Haij S, Jansen JH, Boross P, Beurskens FJ, Bakema JE, Bos DL, Martens A, Verbeek JS, Parren PW, van de Winkel JG, Leusen JH: In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res; 2010 Apr 15;70(8):3209-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Effector cell activation through FcR triggering may induce tumor cell killing via antibody-dependent cellular cytotoxicity (ADCC).
  • In contrast, ADCC of cells expressing frequently used cancer targets, such as CD20, epidermal growth factor receptor, Her2, and gp75, was abrogated.
  • ADCC therefore represents an essential mechanism of action for immunotherapy of lymphoid tumors.

  • Hazardous Substances Data Bank. RITUXIMAB .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 AACR.
  • (PMID = 20354182.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Worldwide Cancer Research / / 06-0368
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Receptors, Fc; 4F4X42SYQ6 / Rituximab; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; M95KG522R0 / ofatumumab
  •  go-up   go-down


78. Florese RH, Van Rompay KK, Aldrich K, Forthal DN, Landucci G, Mahalanabis M, Haigwood N, Venzon D, Kalyanaraman VS, Marthas ML, Robert-Guroff M: Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge. J Immunol; 2006 Sep 15;177(6):4028-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previously, Ab-dependent cellular cytotoxicity (ADCC) was significantly correlated with reduced acute viremia upon intrarectal SIVmac251 challenge of immunized rhesus macaques.
  • To directly assess ADCC protective efficacy, six neonatal macaques were infused s.c. with immune IgG (220 mg/kg) purified from the immunized animals and positive for ADCC and Ab-dependent cell-mediated viral inhibition (ADCVI) activities.
  • At challenge, plasma of neonates that received immune IgG did not neutralize SIVmac251 but had geometric mean ADCC titers of 48,130 and 232,850 against SIVmac251 -infected and gp120-coated targets, respectively.
  • ADCC activity declined with the 2-wk IgG half-life but was boosted at wk 4, together with de novo ADCC-mediating Abs in controls, by postchallenge viremia.
  • Possible factors contributing to the discrepancy between the previous correlation and lack of protection here include: the high oral challenge dose compared with the 400-fold lower intrarectal dose; the challenge route with regard to viral dissemination and distribution of infused IgG; insufficient NK effector activity and/or poor functionality in newborns; insufficient immune IgG; and the possibility that the previous correlation of ADCC with protection was augmented by cellular immune responses also present at challenge.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16951366.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / R02 AI52039; United States / NCRR NIH HHS / RR / RR00169; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin G
  •  go-up   go-down


79. Ishida T, Ishii T, Inagaki A, Yano H, Kusumoto S, Ri M, Komatsu H, Iida S, Inagaki H, Ueda R: The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma. Leukemia; 2006 Dec;20(12):2162-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We therefore tested the chimeric anti-CCR4 monoclonal antibody (mAb), KM2760, the Fc region of which is defucosylated to enhance antibody-dependent cellular cytotoxicity (ADCC), as a novel immunotherapy for refractory HL.
  • Although KM2760 did not induce any ADCC mediated by mouse natural killer (NK) cells, it significantly enhanced phagocytosis mediated by mouse monocytes/macrophages against the CCR4-positive HL cell line in vitro.
  • Furthermore, it induced robust ADCC mediated by NK cells against the CCR4-positive HL cell line in vitro.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17039235.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / CCR4 protein, human; 0 / Ccr4 protein, mouse; 0 / Receptors, CCR4; 0 / Receptors, Chemokine
  •  go-up   go-down


80. Reim F, Dombrowski Y, Ritter C, Buttmann M, Häusler S, Ossadnik M, Krockenberger M, Beier D, Beier CP, Dietl J, Becker JC, Hönig A, Wischhusen J: Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells. Cancer Res; 2009 Oct 15;69(20):8058-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because natural killer (NK) cell-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) is thought to contribute to the therapeutic effects of trastuzumab, we have established a cell culture system to select for ADCC-resistant SK-OV-3 ovarian cancer and MCF7 mammary carcinoma cells.
  • When immunoselected MCF7 cells were then re-expanded, they mostly lost the observed phenotype to regenerate a tumor cell culture that displayed the initial HER2 surface expression and ADCC-susceptibility, but was enriched in CD44(high)CD24(low) cancer stem cells.
  • Thus, we provide evidence that the induction of ADCC by trastuzumab and NK cells may spare the actual tumor-initiating cells, which could explain clinical relapse and progress.
  • Moreover, our observation that the "relapsed" in vitro cultures show practically identical HER2 surface expression and susceptibility toward ADCC suggests that the administration of trastuzumab beyond relapse might be considered, especially when combined with an immune-stimulatory treatment that targets the escape variants.


81. Lapalombella R, Yu B, Triantafillou G, Liu Q, Butchar JP, Lozanski G, Ramanunni A, Smith LL, Blum W, Andritsos L, Wang DS, Lehman A, Chen CS, Johnson AJ, Marcucci G, Lee RJ, Lee LJ, Tridandapani S, Muthusamy N, Byrd JC: Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood; 2008 Dec 15;112(13):5180-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lenalidomide, an immunomodulatory agent that enhances antibody-dependent cellular cytotoxicity (ADCC), is currently being investigated as a therapy for chronic lymphocytic leukemia (CLL).
  • We therefore examined whether lenalidomide combined with rituximab enhances direct apoptosis and ADCC in CLL cells.
  • In addition, CD20 surface antigen down-modulation by lenalidomide in CLL was accompanied by diminished rituximab-mediated apoptosis and ADCC.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2001 Dec 1;98(12):3383-9 [11719378.001]
  • [Cites] Blood. 2002 Feb 1;99(3):754-8 [11806974.001]
  • [Cites] Ther Drug Monit. 2008 Oct;30(5):620-7 [18708993.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1314-9 [11830481.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3063-7 [12384400.001]
  • [Cites] Eur J Immunol. 2003 Sep;33(9):2398-409 [12938216.001]
  • [Cites] Haematologica. 2003 Sep;88(9):1002-12 [12969808.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3940-7 [12975461.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1472-4 [14563637.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1846-54 [14630799.001]
  • [Cites] Hematol Oncol Clin North Am. 2004 Aug;18(4):895-913, ix-x [15325705.001]
  • [Cites] Int J Cancer. 1981 Mar 15;27(3):321-7 [6169660.001]
  • [Cites] Scand J Haematol. 1981 Sep;27(3):181-5 [6947403.001]
  • [Cites] Blood. 1984 Feb;63(2):305-9 [6607080.001]
  • [Cites] J Immunol. 1985 Oct;135(4):2589-92 [4031496.001]
  • [Cites] J Biol Chem. 1986 Aug 5;261(22):10240-7 [3733709.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Nov;84(22):8085-9 [3500472.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Acta Haematol. 1996;96(1):16-23 [8677756.001]
  • [Cites] Br J Cancer. 1998 Aug;78(4):478-83 [9716030.001]
  • [Cites] N Engl J Med. 2005 Feb 10;352(6):549-57 [15703420.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5984-92 [16115943.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1675-82 [16030029.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4050-3 [16118317.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11712-20 [16357183.001]
  • [Cites] Leukemia. 2006 Feb;20(2):272-9 [16341049.001]
  • [Cites] J Control Release. 2006 May 15;112(2):199-207 [16564596.001]
  • [Cites] Lancet Oncol. 2006 Jun;7(6):480-8 [16750498.001]
  • [Cites] N Engl J Med. 2006 Oct 5;355(14):1456-65 [17021321.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3458-64 [16840727.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5343-9 [17088571.001]
  • [Cites] Clin Cancer Res. 2006 Dec 1;12(23):7046-53 [17145827.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8653-61 [17875705.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2561-4 [17475906.001]
  • [Cites] Br J Haematol. 2008 Jan;140(1):36-45 [17995965.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2519-25 [18427150.001]
  • [Cites] Blood. 2008 Jun 1;111(11):5291-7 [18334676.001]
  • [Cites] J Clin Invest. 2008 Jul;118(7):2427-37 [18551193.001]
  • [CommentIn] Blood. 2008 Dec 15;112(13):4785-6 [19064733.001]
  • [ErratumIn] Blood. 2009 Oct 15;114(16):3506
  • (PMID = 18772452.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA095426; United States / NCI NIH HHS / CA / P01 CA101956; United States / NCRR NIH HHS / RR / UL1 RR025755; United States / NCI NIH HHS / CA / CA95426
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Liposomes; 4F4X42SYQ6 / Rituximab; 4Z8R6ORS6L / Thalidomide; F0P408N6V4 / lenalidomide
  • [Other-IDs] NLM/ PMC2597613
  •  go-up   go-down


82. Gomez-Rivera F, Medina-Franco H, Arch-Ferrer JE, Heslin MJ: Adrenocortical carcinoma: a single institution experience. Am Surg; 2005 Jan;71(1):90-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma: a single institution experience.
  • Adrenocortical carcinoma (ADCC) ranks among the least common malignant endocrine tumors.
  • Medical records of patients with the diagnosis of ADCC between 1990 and 2000 were reviewed.
  • Survival for ADCC is poor.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenocortical Carcinoma / surgery

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15757066.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Natsume A, Wakitani M, Yamane-Ohnuki N, Shoji-Hosaka E, Niwa R, Uchida K, Satoh M, Shitara K: Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region. J Immunol Methods; 2005 Nov 30;306(1-2):93-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fucose removal from complex-type oligosaccharide of human IgG1-type antibody results in a great enhancement of antibody-dependent cellular cytotoxicity (ADCC).
  • The scFv-Fc lacking fucose exhibited significantly more potent FcgammaRIIIa binding and ADCC compared to highly fucosylated scFv-Fc.
  • These results prove that ADCC enhancement by fucose-removal is effective in not only whole IgG1, but also scFv-Fc, and thus increases the potential of Fc-fusion proteins as therapeutic candidates.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16236307.001).
  • [ISSN] 0022-1759
  • [Journal-full-title] Journal of immunological methods
  • [ISO-abbreviation] J. Immunol. Methods
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Glycoproteins; 0 / Immunoglobulin Constant Regions; 0 / Immunoglobulin G; 0 / Immunoglobulin Variable Region; 0 / Oligosaccharides; 0 / Receptors, IgG; 0 / Recombinant Fusion Proteins; 0 / tumor-associated antigen 72; 3713-31-3 / Fucose; EC 2.4.1.- / Fucosyltransferases; EC 2.4.1.68 / Glycoprotein 6-alpha-L-fucosyltransferase
  •  go-up   go-down


84. Vaine M, Wang S, Liu Q, Arthos J, Montefiori D, Goepfert P, McElrath MJ, Lu S: Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies. PLoS One; 2010 Nov 09;5(11):e13916
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HIV-1 Env-specific binding antibody, neutralizing antibody, antibody-dependent cell-mediated cytotoxicity (ADCC), and profiles of antibody specificity were analyzed for human immune sera collected from vaccinees enrolled in the NIH HIV Vaccine Trial Network (HVTN) Study #041 (recombinant protein alone), HVTN Study #203 (poxviral vector prime-protein boost), and the DP6-001 study (DNA prime-protein boost).
  • No differences were found in CD4-induced (CD4i) antibody responses, ADCC activity, or complement activation by Env-specific antibody among these sera.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • HIV InSite. treatment guidelines - HIV InSite .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2000 Feb;6(2):207-10 [10655111.001]
  • [Cites] Science. 2010 Aug 13;329(5993):811-7 [20616231.001]
  • [Cites] Virology. 2001 Dec 20;291(2):324-34 [11878901.001]
  • [Cites] J Med Primatol. 2002 Jun;31(3):109-19 [12190851.001]
  • [Cites] J Virol. 2003 Jun;77(11):6466-73 [12743303.001]
  • [Cites] Nature. 1992 Feb 20;355(6362):728-30 [1741059.001]
  • [Cites] J Virol. 1996 Oct;70(10):6751-8 [8794312.001]
  • [Cites] J Infect Dis. 1998 May;177(5):1230-46 [9593008.001]
  • [Cites] J Virol. 1999 May;73(5):4009-18 [10196297.001]
  • [Cites] J Infect Dis. 2005 Mar 1;191(5):654-65 [15688278.001]
  • [Cites] Vaccine. 2005 Mar 31;23(19):2522-9 [15752839.001]
  • [Cites] J Exp Med. 2005 May 2;201(9):1407-19 [15867093.001]
  • [Cites] J Virol. 2005 Aug;79(16):10108-25 [16051804.001]
  • [Cites] J Virol. 2005 Dec;79(24):15547-55 [16306625.001]
  • [Cites] J Immunol Methods. 2006 Jan 20;308(1-2):53-67 [16343526.001]
  • [Cites] Arch Virol. 2006 Aug;151(8):1511-23 [16508703.001]
  • [Cites] J Virol. 2006 Sep;80(17):8745-62 [16912322.001]
  • [Cites] Expert Rev Vaccines. 2006 Aug;5(4):579-95 [16989638.001]
  • [Cites] Hum Vaccin. 2005 Mar-Apr;1(2):45-60 [17038830.001]
  • [Cites] Vaccine. 2007 Jan 5;25(3):510-8 [17049679.001]
  • [Cites] J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):203-12 [17106277.001]
  • [Cites] Nat Med. 2007 Sep;13(9):1032-4 [17721546.001]
  • [Cites] Virology. 2007 Sep 30;366(2):245-62 [17580087.001]
  • [Cites] Vaccine. 2008 Jul 23;26(31):3947-57 [18724414.001]
  • [Cites] Nature. 2008 Oct 2;455(7213):613-9 [18833271.001]
  • [Cites] PLoS Pathog. 2008;4(10):e1000171 [18833294.001]
  • [Cites] Virology. 2008 Oct 25;380(2):285-95 [18804254.001]
  • [Cites] J Virol. 2008 Dec;82(23):11651-68 [18815292.001]
  • [Cites] Lancet. 2008 Nov 29;372(9653):1881-93 [19012954.001]
  • [Cites] J Virol. 2009 Jan;83(2):1045-59 [19004942.001]
  • [Cites] Nature. 2009 Apr 2;458(7238):636-40 [19287373.001]
  • [Cites] Nat Med. 2009 Aug;15(8):951-4 [19525965.001]
  • [Cites] Science. 2009 Oct 9;326(5950):285-9 [19729618.001]
  • [Cites] N Engl J Med. 2009 Dec 3;361(23):2209-20 [19843557.001]
  • [Cites] J Virol. 2001 Aug;75(16):7470-80 [11462019.001]
  • (PMID = 21085486.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI082274; United States / NIAID NIH HHS / AI / AI082676; United States / NIAID NIH HHS / AI / AI065250; United States / NIAID NIH HHS / AI / U19 AI082676; United States / NIAID NIH HHS / AI / R01 AI065250; United States / NIAID NIH HHS / AI / P01 AI082274; United States / NIAID NIH HHS / AI / U01 AI068618; United States / NIAID NIH HHS / AI / P30 AI027742; United States / NIAID NIH HHS / AI / R21 AI087191; United States / NIAID NIH HHS / AI / AI 27742
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AIDS Vaccines; 0 / Antibodies, Neutralizing; 0 / HIV Antibodies; 0 / HIV Envelope Protein gp120
  • [Other-IDs] NLM/ PMC2976701
  •  go-up   go-down


85. Danielczyk A, Stahn R, Faulstich D, Löffler A, Märten A, Karsten U, Goletz S: PankoMab: a potent new generation anti-tumour MUC1 antibody. Cancer Immunol Immunother; 2006 Nov;55(11):1337-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PankoMab reveals a potent tumour-specific antibody-dependent cell cytotoxicity (ADCC).
  • PankoMab is, therefore, distinguished by a combination of advantages compared to other MUC1 antibodies in clinical development, including higher tumour specificity, higher affinity, a higher number of binding sites, largely reduced binding to shed MUC1 from colon and pancreatic carcinoma patients, no binding to mononucleated cells from peripheral blood (except approximately 7% of activated T cells), stronger ADCC activity and rapid internalisation as required for toxin-mediated cell killing.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16485130.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, Neoplasm; 0 / Carbohydrates; 0 / Epitopes; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / Mucins
  •  go-up   go-down


86. Ide F, Mishima K, Yamada H, Saito I: Adenoid cystic carcinoma ex pleomorphic adenoma of the parotid gland. Head Neck Pathol; 2009 Jun;3(2):159-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic carcinoma ex pleomorphic adenoma of the parotid gland.
  • There is a considerable variation in the histologic subtype of epithelial malignancies among carcinoma ex pleomorphic adenomas (CXPA) and virtually any known carcinoma entity can develop.
  • To our knowledge, adenoid cystic carcinoma (AdCC) ex PA is quite rare despite the fact that de novo AdCC is the fourth most common salivary gland malignancy.
  • We describe a new case of AdCC ex PA in the parotid gland of a 62 year-old woman.
  • Although most of the reported cases are considered low-grade, evidence is presented here that AdCC can take the form of a high-grade malignancy in PA.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Carcinoma, Adenoid Cystic / pathology. Parotid Neoplasms / pathology

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Otolaryngol. 1968 Dec;66(6):477-92 [4308066.001]
  • [Cites] Cancer. 1968 Jun;21(6):1198-211 [4296747.001]
  • [Cites] Cancer. 1977 May;39(5):2209-30 [192443.001]
  • [Cites] Arch Otolaryngol. 1984 Mar;110(3):172-6 [6322732.001]
  • [Cites] Cancer. 1984 Sep 15;54(6):1062-9 [6088017.001]
  • [Cites] Rev Stomatol Chir Maxillofac. 1985;86(1):36-40 [2984762.001]
  • [Cites] Acta Cytol. 1985 Jul-Aug;29(4):522-6 [2992197.001]
  • [Cites] Pathol Annu. 1993;28 Pt 1:279-328 [8380049.001]
  • [Cites] Auris Nasus Larynx. 1995;22(1):65-70 [7677639.001]
  • [Cites] Histopathology. 1996 Mar;28(3):247-52 [8729044.001]
  • [Cites] J Otolaryngol. 1999 Jun;28(3):166-70 [10410350.001]
  • [Cites] Histopathology. 2005 Jun;46(6):635-41 [15910594.001]
  • [Cites] J Craniofac Surg. 2007 Jan;18(1):231-5 [17251870.001]
  • [Cites] Auris Nasus Larynx. 2007 Mar;34(1):79-84 [17049779.001]
  • [Cites] Histopathology. 2007 Jul;51(1):1-20 [17539914.001]
  • [Cites] Otolaryngol Head Neck Surg. 2008 May;138(5):601-5 [18439465.001]
  • [Cites] Hum Pathol. 2001 Jun;32(6):596-604 [11431714.001]
  • [Cites] Head Neck. 2002 Mar;24(3):301-6 [11891964.001]
  • [Cites] Mod Pathol. 2002 Jul;15(7):724-33 [12118110.001]
  • [Cites] Pathol Int. 2003 Jan;53(1):30-4 [12558867.001]
  • [Cites] Rhinology. 2003 Jun;41(2):118-21 [12868379.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Nov;129(11):1193-7 [14623749.001]
  • [Cites] Cancer. 1977 Feb;39(2):388-96 [189890.001]
  • (PMID = 19644550.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Adenoid cystic carcinoma / Carcinoma ex pleomorphic adenoma / High-grade malignancy / Parotid gland
  •  go-up   go-down


87. Karnasuta C, Paris RM, Cox JH, Nitayaphan S, Pitisuttithum P, Thongcharoen P, Brown AE, Gurunathan S, Tartaglia J, Heyward WL, McNeil JG, Birx DL, de Souza MS, Thai AIDS Vaccine Evaluation Group, Thailand: Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine; 2005 Mar 31;23(19):2522-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antibody-dependent cell-mediated cytotoxicity (ADCC) was assessed in volunteers participating in an ALVAC-HIV (vCP1521)/AIDSVAX B/E gp120 prime-boost vaccine trial in Thailand.
  • ADCC activity was measured using chromium release from gp120 subtype B- and CRF01_AE-coated targets in 95 vaccinees and 28 placebo recipients.
  • There was a significant difference in the magnitude of the ADCC response to both targets between vaccinees and placebo recipients.
  • The results demonstrate that this HIV vaccine is a potent inducer of ADCC activity and may be an additional protection of this prime-boost vaccine in preventing HIV disease.


88. Volante M, Buttigliero C, Greco E, Berruti A, Papotti M: Pathological and molecular features of adrenocortical carcinoma: an update. J Clin Pathol; 2008 Jul;61(7):787-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathological and molecular features of adrenocortical carcinoma: an update.
  • The pathological diagnosis of adrenocortical carcinoma (ACC), which is based on gross and microscopic criteria, is subjective.
  • The classification of oncocytic and paediatric adrenocortical tumours is even more challenging, as not all of the above morphological parameters are predictors of malignancy in these tumour types.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / pathology
  • [MeSH-minor] Algorithms. Biomarkers, Tumor / metabolism. Chromosome Aberrations. Diagnosis, Differential. Humans. Immunophenotyping. Neoplastic Syndromes, Hereditary / genetics

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18430754.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 75
  •  go-up   go-down


89. Natsume A, In M, Takamura H, Nakagawa T, Shimizu Y, Kitajima K, Wakitani M, Ohta S, Satoh M, Shitara K, Niwa R: Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res; 2008 May 15;68(10):3863-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have previously reported that fucose removal from Fc-linked oligosaccharides greatly enhances antibody-dependent cellular cytotoxicity (ADCC) of therapeutic antibodies.
  • To eliminate this deficiency, a portion in COOH-terminal CH3 domain of 1133 was substituted with IgG1, resulting in full recovery of protein A binding without compromising the enhanced CDC and ADCC activities.
  • The ADCC activity of the variants was also maximized by the absence of fucose from its carbohydrate structure, a phenomenon that has previously been observed for wild-type antibodies.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18483271.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD20; 0 / Antigens, Neoplasm; 0 / CD52 antigen; 0 / Carbohydrates; 0 / Glycoproteins; 0 / Immunoglobulin G; 0 / Immunoglobulin Isotypes
  •  go-up   go-down


90. Manu KA, Kuttan G: Effect of Punarnavine, an alkaloid from Boerhaavia diffusa, on cell-mediated immune responses and TIMP-1 in B16F-10 metastatic melanoma-bearing mice. Immunopharmacol Immunotoxicol; 2007;29(3-4):569-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Administration of Punarnavine enhanced Natural Killer (NK) cell activity, antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent complement mediated cytotoxicity (ACC) and the activity was observed in treated group much earlier compared to the metastatic tumor-bearing control.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18075866.001).
  • [ISSN] 0892-3973
  • [Journal-full-title] Immunopharmacology and immunotoxicology
  • [ISO-abbreviation] Immunopharmacol Immunotoxicol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alkaloids; 0 / DNA Primers; 0 / Interleukin-1beta; 0 / Interleukin-2; 0 / Interleukin-6; 0 / Tissue Inhibitor of Metalloproteinase-1; 0 / Tumor Necrosis Factor-alpha; 0 / punarnavine; 82115-62-6 / Interferon-gamma; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; 9007-36-7 / Complement System Proteins
  •  go-up   go-down


91. Beuger V, Künkele KP, Koll H, Gärtner A, Bähner M, Burtscher H, Klein C: Short-hairpin-RNA-mediated silencing of fucosyltransferase 8 in Chinese-hamster ovary cells for the production of antibodies with enhanced antibody immune effector function. Biotechnol Appl Biochem; 2009 May;53(Pt 1):31-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antibody-producing Chinese-hamster ovary cells (CHO-DG44) were converted into cells producing antibodies with strongly enhanced ADCC (antibody-dependent cellular cytotoxicity) by knocking down FuT8 (alpha-1,6-fucosyltransferase or fucosyltransferase 8) via constitutive expression of shRNA (short-hairpin RNA) against FuT8.
  • The CHO-DG44 clones identified produced highly afucosylated anti-[IGF-1R (insulin-like-growth-factor-1 receptor)] antibodies (up to 88%) that exhibited considerably enhanced ADCC compared with anti-IGF-1R wild-type antibodies produced by parental CHO cells.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19032154.001).
  • [ISSN] 1470-8744
  • [Journal-full-title] Biotechnology and applied biochemistry
  • [ISO-abbreviation] Biotechnol. Appl. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies; 0 / RNA, Small Interfering; 0 / Recombinant Proteins; EC 2.4.1.- / Fucosyltransferases; EC 2.4.1.68 / Glycoprotein 6-alpha-L-fucosyltransferase; EC 2.7.10.1 / Receptor, IGF Type 1
  •  go-up   go-down


92. Trotta R, Dal Col J, Yu J, Ciarlariello D, Thomas B, Zhang X, Allard J 2nd, Wei M, Mao H, Byrd JC, Perrotti D, Caligiuri MA: TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. J Immunol; 2008 Sep 15;181(6):3784-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The role of TGF-beta in regulating CD16-mediated NK cell IFN-gamma production and antibody-dependent cellular cytotoxicity (ADCC) is unclear, as are the signaling pathways that may be utilized.
  • An extended treatment of primary NK cells with TGF-beta was required to inhibit ADCC, and it did so by inhibiting granzyme A and granzyme B expression.
  • Collectively, our results indicate that TGF-beta inhibits CD16-mediated human NK cell IFN-gamma production and ADCC, and these effects are mediated via SMAD3.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 1996 Sep 1;184(3):1027-35 [9064320.001]
  • [Cites] Immunity. 1997 Jun;6(6):655-61 [9208838.001]
  • [Cites] Curr Top Microbiol Immunol. 1998;230:63-88 [9586351.001]
  • [Cites] J Immunol. 1998 Aug 15;161(4):1772-7 [9712043.001]
  • [Cites] J Immunol. 1998 Dec 15;161(12):6648-56 [9862693.001]
  • [Cites] J Immunol. 1999 Mar 1;162(5):2974-81 [10072548.001]
  • [Cites] J Immunol. 1999 Apr 15;162(8):4511-20 [10201989.001]
  • [Cites] J Immunol Methods. 2005 Jan;296(1-2):115-23 [15680156.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3011-8 [15604218.001]
  • [Cites] Nat Immunol. 2005 Jun;6(6):600-7 [15852008.001]
  • [Cites] Cancer Cell. 2005 Nov;8(5):349-50 [16286241.001]
  • [Cites] Cancer Cell. 2005 Nov;8(5):369-80 [16286245.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):517-26 [16397268.001]
  • [Cites] J Exp Med. 1996 Jan 1;183(1):179-86 [8551221.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2409-14 [16304057.001]
  • [Cites] Annu Rev Immunol. 2006;24:99-146 [16551245.001]
  • [Cites] Int Immunopharmacol. 2006 Jun;6(6):1020-8 [16644489.001]
  • [Cites] Immunity. 2006 May;24(5):575-90 [16713975.001]
  • [Cites] J Immunol. 2006 Jul 1;177(1):120-9 [16785506.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3993-6 [16818697.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4142-6 [16857784.001]
  • [Cites] Clin Cancer Res. 2006 Dec 1;12(23):7046-53 [17145827.001]
  • [Cites] J Clin Invest. 2007 May;117(5):1305-13 [17415413.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3712-8 [17704420.001]
  • [Cites] Eur J Immunol. 2007 Sep;37(9):2549-61 [17705132.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3192-201 [17616639.001]
  • [Cites] Blood. 2008 May 1;111(9):4723-30 [18182577.001]
  • [Cites] Microbes Infect. 1999 Dec;1(15):1305-11 [10611759.001]
  • [Cites] Cell. 2000 Mar 17;100(6):655-69 [10761931.001]
  • [Cites] J Immunol. 2000 Aug 15;165(4):1782-9 [10925255.001]
  • [Cites] Blood. 2001 May 15;97(10):3146-51 [11342442.001]
  • [Cites] J Exp Med. 2001 Sep 3;194(5):629-44 [11535631.001]
  • [Cites] Eur J Immunol. 2001 Oct;31(10):3016-25 [11592078.001]
  • [Cites] Trends Immunol. 2001 Nov;22(11):633-40 [11698225.001]
  • [Cites] Blood. 2002 Feb 1;99(3):754-8 [11806974.001]
  • [Cites] Mol Pharmacol. 2002 Jul;62(1):65-74 [12065756.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1935-47 [12200350.001]
  • [Cites] J Clin Invest. 2002 Oct;110(7):983-92 [12370276.001]
  • [Cites] Cancer Cell. 2003 Feb;3(2):145-60 [12620409.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4120-5 [12646700.001]
  • [Cites] J Immunol. 2003 May 1;170(9):4572-7 [12707335.001]
  • [Cites] Nature. 2003 Oct 9;425(6958):577-84 [14534577.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3940-7 [12975461.001]
  • [Cites] J Immunol. 2004 Jun 15;172(12):7335-40 [15187109.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4664-9 [15231679.001]
  • [Cites] Nat Med. 2004 Sep;10(9):942-9 [15322536.001]
  • [Cites] Adv Immunol. 1989;47:187-376 [2683611.001]
  • [Cites] J Exp Med. 1992 Dec 1;176(6):1745-50 [1281217.001]
  • [Cites] Scand J Immunol. 1993 Jan;37(1):71-6 [8380302.001]
  • [Cites] J Immunol. 1993 Jan 15;150(2):605-16 [8419492.001]
  • [Cites] J Exp Med. 1994 Feb 1;179(2):551-8 [8294866.001]
  • [Cites] J Immunol. 1995 Aug 1;155(3):1066-73 [7636180.001]
  • (PMID = 18768831.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA16058; United States / NCI NIH HHS / CA / CA68458; United States / NCI NIH HHS / CA / R01 CA068458; United States / NCI NIH HHS / CA / R01 CA095512; United States / NCI NIH HHS / CA / P01 CA095426-09; United States / NCI NIH HHS / CA / R01 CA095512-08; United States / NCI NIH HHS / CA / CA016058-30; United States / NCI NIH HHS / CA / CA095512-08; United States / NCI NIH HHS / CA / P01 CA095426; United States / NCI NIH HHS / CA / CA095512; United States / NCI NIH HHS / CA / P30 CA016058; United States / NCI NIH HHS / CA / CA068458-08S1; United States / NCI NIH HHS / CA / CA95426; United States / NCI NIH HHS / CA / CA095426-09; United States / NCI NIH HHS / CA / R37 CA068458; United States / NCI NIH HHS / CA / R01 CA068458-08S1; United States / NCI NIH HHS / CA / P30 CA016058-30
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FCGR3B protein, human; 0 / GPI-Linked Proteins; 0 / Receptors, IgG; 0 / SMAD3 protein, human; 0 / Smad3 Protein; 0 / Transforming Growth Factor beta; 187348-17-0 / Interleukin-12; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ NIHMS215048; NLM/ PMC2924753
  •  go-up   go-down


93. Clark AJ, Diamond M, Elfline M, Petty HR: Calicum microdomains form within neutrophils at the neutrophil-tumor cell synapse: role in antibody-dependent target cell apoptosis. Cancer Immunol Immunother; 2010 Jan;59(1):149-59
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neutrophil-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) is one form of leukocyte activation that plays an important role in tumor cell killing in vitro and in patient care.
  • Using fluorescence methodologies, we found that neutrophils exhibit Ca(2+) signals during ADCC directed against breast fibrosarcoma cells.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 Feb 1;99(3):754-8 [11806974.001]
  • [Cites] Nat Rev Immunol. 2007 Sep;7(9):690-702 [17703229.001]
  • [Cites] Methods Mol Biol. 2008;414:13-21 [18175808.001]
  • [Cites] J Lipid Res. 2008 Mar;49(3):531-42 [18156590.001]
  • [Cites] J Clin Oncol. 2008 Apr 10;26(11):1789-96 [18347005.001]
  • [Cites] J Biol Chem. 2008 Jun 20;283(25):17333-40 [18430726.001]
  • [Cites] Cytometry A. 2008 Jul;73(7):673-8 [18496849.001]
  • [Cites] Cancer Cell. 2009 Feb 3;15(2):124-34 [19185847.001]
  • [Cites] J Clin Oncol. 2009 Mar 1;27(7):1122-9 [19164213.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15217-21 [10611365.001]
  • [Cites] Nat Med. 2000 Apr;6(4):443-6 [10742152.001]
  • [Cites] Blood. 2001 Jan 15;97(2):339-45 [11154206.001]
  • [Cites] Blood. 2001 Apr 15;97(8):2478-86 [11290613.001]
  • [Cites] J Leukoc Biol. 2001 Apr;69(4):522-30 [11310837.001]
  • [Cites] J Cell Sci. 2001 May;114(Pt 9):1643-53 [11309196.001]
  • [Cites] Vox Sang. 2001;81(2):128-33 [11555474.001]
  • [Cites] J Urol. 2002 Feb;167(2 Pt 1):707-12 [11792958.001]
  • [Cites] Immunol Res. 2002;25(1):75-95 [11868935.001]
  • [Cites] Blood. 2003 Jan 1;101(1):253-8 [12485936.001]
  • [Cites] J Cell Sci. 2003 Feb 1;116(Pt 3):537-50 [12508114.001]
  • [Cites] Annu Rev Immunol. 2003;21:457-81 [12615889.001]
  • [Cites] J Immunol. 2003 Nov 15;171(10):5124-9 [14607911.001]
  • [Cites] Oncogene. 2003 Nov 24;22(53):8619-27 [14634623.001]
  • [Cites] J Immunol. 1979 Jul;123(1):55-62 [36434.001]
  • [Cites] J Natl Cancer Inst. 1984 Aug;73(2):331-9 [6205210.001]
  • [Cites] J Immunol. 1988 May 15;140(10):3515-21 [2966198.001]
  • [Cites] J Cell Physiol. 1989 Dec;141(3):598-605 [2687299.001]
  • [Cites] Am Rev Respir Dis. 1990 Mar;141(3 Pt 2):S127-31 [2178532.001]
  • [Cites] Scand J Immunol. 1990 Mar;31(3):315-25 [2157275.001]
  • [Cites] J Leukoc Biol. 1991 May;49(5):511-24 [1826726.001]
  • [Cites] Immunology. 1991 Dec;74(4):657-60 [1838354.001]
  • [Cites] Blood. 1992 Mar 15;79(6):1484-90 [1347707.001]
  • [Cites] J Exp Med. 1995 Nov 1;182(5):1609-14 [7595233.001]
  • [Cites] J Histochem Cytochem. 1996 Jun;44(6):641-56 [8666749.001]
  • [Cites] J Leukoc Biol. 1996 Oct;60(4):433-40 [8864126.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14809-14 [8962137.001]
  • [Cites] Cancer Res. 1997 Feb 15;57(4):696-701 [9044847.001]
  • [Cites] Blood. 1997 May 15;89(10):3503-21 [9160655.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):652-6 [9435247.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):3051-8 [9679970.001]
  • [Cites] Neuroreport. 1999 Apr 6;10(5):1149-53 [10321500.001]
  • [Cites] J Biol Chem. 2005 Feb 4;280(5):3516-21 [15569668.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2005;45:269-90 [15822178.001]
  • [Cites] Exp Cell Res. 2005 Aug 1;308(1):156-65 [15916759.001]
  • [Cites] Nat Biotechnol. 2005 Sep;23(9):1147-57 [16151408.001]
  • [Cites] Oncology (Williston Park). 2006 Apr;20(5 Suppl 2):15-25 [16736979.001]
  • [Cites] J Immunol. 2006 Dec 1;177(11):8123-32 [17114487.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):37-51 [17222789.001]
  • [Cites] J Biol Chem. 2007 Mar 2;282(9):6210-21 [17202140.001]
  • [Cites] Sci STKE. 2007 Apr 10;2007(381):pe14 [17426345.001]
  • [Cites] Curr Biol. 2007 Jun 19;17(12):1076-81 [17570667.001]
  • [Cites] Drug Discov Today. 2007 Nov;12(21-22):898-910 [17993407.001]
  • (PMID = 19593564.001).
  • [ISSN] 1432-0851
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA074120
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Calcium Channels; 0 / Membrane Glycoproteins; 0 / Stim1 protein, mouse; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ NIHMS381280; NLM/ PMC3379002
  •  go-up   go-down


94. Richards JO, Karki S, Lazar GA, Chen H, Dang W, Desjarlais JR: Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther; 2008 Aug;7(8):2517-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although an early goal has been enhanced FcgammaRIIIa binding and natural killer (NK) cell antibody-dependent cell-mediated cytotoxicity (ADCC), other relevant cell types such as macrophages are dependent on additional activating receptors such as FcgammaRIIa.
  • Specific double and triple combination variants with this substitution are simultaneously capable of exhibiting high NK-mediated ADCC and high macrophage phagocytosis.

  • GeneTex Inc. NCBI Redirect Page | Genetex Inc. (subscription/membership/fee required).
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18723496.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Fc gamma receptor IIA; 0 / Receptors, IgG
  •  go-up   go-down


95. Biglari A, Southgate TD, Fairbairn LJ, Gilham DE: Human monocytes expressing a CEA-specific chimeric CD64 receptor specifically target CEA-expressing tumour cells in vitro and in vivo. Gene Ther; 2006 Apr;13(7):602-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antibody-dependent cellular cytotoxicity (ADCC) is one means by which macrophages (as well as natural killer cells and granulocytes) elicit a cytotoxic response.

  • MedlinePlus Health Information. consumer health - Cancer Immunotherapy.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16397508.001).
  • [ISSN] 0969-7128
  • [Journal-full-title] Gene therapy
  • [ISO-abbreviation] Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Cytokines; 0 / Receptors, IgG; 0 / Recombinant Proteins; 147336-22-9 / Green Fluorescent Proteins
  •  go-up   go-down


96. Guerrero MA, Kebebew E: Adrenocortical carcinoma and synchronous malignancies. J Cancer; 2010;1:108-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma and synchronous malignancies.
  • OBJECTIVE: Adrenocortical carcinoma (ACC) is an aggressive tumor that accounts for 0.02% of all reported cancers.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20842232.001).
  • [ISSN] 1837-9664
  • [Journal-full-title] Journal of Cancer
  • [ISO-abbreviation] J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Other-IDs] NLM/ PMC2938073
  • [Keywords] NOTNLM ; Adrenocortical carcinoma / Ovarian cancer / Synchronous malignancies / Uterine cancer / and Hereditary syndrome
  •  go-up   go-down


97. Gómez-Román VR, Florese RH, Patterson LJ, Peng B, Venzon D, Aldrich K, Robert-Guroff M: A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J Immunol Methods; 2006 Jan 20;308(1-2):53-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We used the RFADCC to assess dose-dependent and envelope-specific anti-human immunodeficiency virus (HIV) ADCC responses mediated by monoclonal antibody-2G12 and human sera.
  • Using the assay, we also detected early anti-simian immunodeficiency virus (SIV) ADCC responses in rhesus macaques infected with pathogenic SIV(mac251).
  • Importantly, the RFADCC was further useful in monitoring anti-HIV and anti-SIV ADCC responses elicited by immunizing chimpanzees and rhesus macaques with replicating adenovirus-based AIDS vaccine candidates.
  • The RFADCC is therefore a simple, reliable, and highly sensitive method that can be applied to assess the ADCC activity of monoclonal antibodies as well as ADCC responses elicited by HIV or SIV infection or by AIDS vaccine candidates.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHROMIUM, ELEMENTAL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343526.001).
  • [ISSN] 0022-1759
  • [Journal-full-title] Journal of immunological methods
  • [ISO-abbreviation] J. Immunol. Methods
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / 5-(6)-carboxyfluorescein diacetate succinimidyl ester; 0 / AIDS Vaccines; 0 / Antibodies, Monoclonal; 0 / Antibodies, Viral; 0 / Fluoresceins; 0 / Fluorescent Dyes; 0 / Organic Chemicals; 0 / PKH 26; 0 / Succinimides; 0R0008Q3JB / Chromium
  •  go-up   go-down


98. Shi YX, Zhang XS, Xia JC, Li YQ, Xu RH, Han WJ, Zhang JH, Guan ZZ, Jiang WQ: [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells]. Ai Zheng; 2007 Aug;26(8):837-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & OBJECTIVE: Natural killer (NK) cells are the main effector of antibody-dependent cellular cytotoxicity (ADCC).

  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17697543.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 0 / Receptors, IgG; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


99. Shitara K: [Potelligent antibodies as next generation therapeutic antibodies]. Yakugaku Zasshi; 2009 Jan;129(1):3-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antibody-dependent cellular cytotoxicity (ADCC), a lytic attack on antibody-targeted cells, is triggered upon binding of lymphocyte receptors (FcgammaRs) to the antibody constant region.
  • ADCC is considered to be a major therapeutic function of antibodies.
  • ADCC requires the presence of oligosaccharides in the Fc region and is sensitive to change in the oligosaccharide structure.
  • We have demonstrated that fucose is the most critical IgG1 oligosaccharide component, and the removal of fucose from IgG1 oligosaccharides results in a very significant enhancement of ADCC and anti-tumor activity in vivo.
  • Potelligent antibodies show potent ADCC upon target cells through the effective and antigen-specific activation of NK cells due to augmented binding to FcgammaRIIIa.
  • Moreover, Potelligent antibodies can evade the inhibitory effect of plasma IgG on ADCC through its high FcgammaRIIIa binding.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19122430.001).
  • [ISSN] 0031-6903
  • [Journal-full-title] Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
  • [ISO-abbreviation] Yakugaku Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies; 0 / FCGR3A protein, human; 0 / Immunoglobulin G; 0 / Oligosaccharides; 0 / Receptors, IgG; 3713-31-3 / Fucose
  • [Number-of-references] 19
  •  go-up   go-down


100. Tokuyama H, Hagi T, Mattarollo SR, Morley J, Wang Q, So HF, Moriyasu F, Nieda M, Nicol AJ: V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab. Int J Cancer; 2008 Jun 1;122(11):2526-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • V gamma 9 V delta 2 T cells expanded in the presence of Zoledronate and IL-2 express CD16 (Fc gamma RIII), which raises the possibility that V gamma 9 V delta 2 T cells could be used in conjunction with tumor targeting monoclonal antibody drugs to increase antitumor cytotoxicity by antibody dependent cellular cytotoxicity (ADCC).
  • Our results show that CD16(+)V gamma 9 V delta 2 T cells recognize monoclonal antibody coated tumor cells via CD16 and exert ADCC similar to that observed with NK cells, even when target cells are relatively resistant to monoclonal antibodies or V gamma 9 V delta 2 T cells alone.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [ErratumIn] Int J Cancer. 2011 Dec 1;129(11):2761. Fai-So, Hang [corrected to So, Hang-Fai]
  • (PMID = 18307255.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Chemokines; 0 / Receptors, Antigen, T-Cell, gamma-delta; 0 / Receptors, IgG; 126465-35-8 / Perforin; 4F4X42SYQ6 / Rituximab; 82115-62-6 / Interferon-gamma; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  •  go-up   go-down






Advertisement